Melanoma neoantigen vaccines: Are we getting more personal now?

KEYNOTE-942 1 Weber J.S. Carlino M.S. Khattak A. Meniawy T. Ansstas G. Taylor M.H. Kim K.B. McKean M. Long G.V. Sullivan R.J. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024; 403: 632-644https://doi.org/10.1016/S0140-6736(23)02268-7 Abstract Full Text Full Text PDF PubMed Scopus (9) Google Scholar is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain. KEYNOTE-942 1 Weber J.S. Carlino M.S. Khattak A. Meniawy T. Ansstas G. Taylor M.H. Kim K.B. McKean M. Long G.V. Sullivan R.J. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024; 403: 632-644https://doi.org/10.1016/S0140-6736(23)02268-7 Abstract Full Text Full Text PDF PubMed Scopus (9) Google Scholar is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain.